β-Thujaplicin modulates the ODC-ROS-linked apoptosis in H460 lung cancer cells.

Authors

Anurag Mathur, Abha Meena, Ashutosh K Tiwari, Suaib Luqman, Puneet Khare, Ratnasekhar Ch

Published in

Naunyn-Schmiedeberg's archives of pharmacology. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

This study explored the antiproliferative effects of β-thujaplicin, a natural tropolone derivative, in the non-small-cell lung cancer (NSCLC) cell lines H460 and A549 and in L132 normal lung epithelial cells, using MTT, NRU, and SRB assays. β-Thujaplicin exhibited concentration-dependent cytotoxicity in H460 and A549 cells but had minimal effect on L132 cells. Mechanistic studies in H460 cells showed suppression of ornithine decarboxylase (ODC) activity and ODC mRNA expression, along with alterations in polyamine metabolite abundance detected by LC-HRMS. Fluorescence microscopy, flow cytometry, and gene expression analysis revealed increased reactive oxygen species (ROS) generation, apoptosis, and cell cycle arrest, suggesting the involvement of the ODC-polyamines axis in these responses. β-Thujaplicin also reduced migration and invasion, accompanied by changes in apoptosis- and epithelial-mesenchymal transition-associated markers. Molecular docking and in silico ADMET analysis suggested an interaction of β-thujaplicin with ODC and predicted favorable drug-like and pharmacokinetic properties that require experimental validation. In the Ehrlich ascites carcinoma (EAC) model, β-thujaplicin reduced tumor burden and increased oxidative stress, providing preliminary evidence of its antitumor activity. However, as this EAC model does not recapitulate NSCLC-specific biology, these findings should be considered proof-of-concept rather than validation of the H460-derived mechanism. Overall, β-thujaplicin shows promising anticancer potential and needs further assessment in NSCLC-specific xenograft and orthotopic in vivo models.

PMID:
42768198
Bibliographic data and abstract were imported from PubMed on 22 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.